Share
Market Research Report

OPIOID USE DISORDER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Product TypeBuprenorphine (Oral, Parenteral, Others) · Naloxone (Parenteral and Others (Nasal Spray, etc.)) · Naltrexone (Oral and Parenteral) · Combination Drugs · and Methadone
  • By Route of AdministrationParenteral (Extended release Injection for Subcutaneous, Intramuscular) · Oral (Sublingual Tablet, Sublingual Film, Suspension) · and Others
  • By Dosage FormInjections · Sublingual film · Sublingual or Buccal · Tablet · Suspension · and Others
  • By AvailabilityPrescription and Over the Counter
  • By BrandSublocade · Suboxone · Brixadi · Vivitrol · Zubsolv · NARCAN · and Others
  • By Age GroupAdult and Children
  • By TypeBranded and Generic
  • By IndicationOpioid Addiction and Pain Management (Acute, Chronic)
  • By Distribution ChannelHospital Pharmacies · Retail Pharmacies · and Online Pharmacies
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In29 Apr 2026
  • Report CodeCMI4597
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Product Type Insights (Revenue, USD Mn, 2023 - 2035)

    • Buprenorphine
      • Oral
      • Parenteral
      • Others
    • Naloxone
      • Parenteral
      • Others
    • Naltrexone
      • Oral
      • Parenteral
    • Combination Drugs
    • Methadone

  • Route of Administration Insights (Revenue, USD Mn, 2023 - 2035)

    • Parenteral
      • Extended-release Injection for Subcutaneous
      • Intramuscular
    • Oral
      • Sublingual Tablet
      • Sublingual Film
      • Suspension
    • Others

  • Dosage Form Insights (Revenue, USD Mn, 2023 - 2035)

    • Injections
    • Sublingual film
    • Sublingual or Buccal
    • Tablet
    • Suspension
    • Others

  • Availability Insights (Revenue, USD Mn, 2023 - 2035)

    • Prescription
    • Over the Counter

  • Brand Insights (Revenue, USD Mn, 2023 - 2035)

    • Sublocade
    • Suboxone
    • Brixadi
    • Vivitrol
    • Zubsolv
    • NARCAN
    • Others

  • Age Group Insights (Revenue, USD Mn, 2023 - 2035)

    • Adult
    • Children

  • Type Insights (Revenue, USD Mn, 2023 - 2035)

    • Branded
    • Generic

  • Indication Insights (Revenue, USD Mn, 2023 - 2035)

    • Opioid Addiction
    • Pain Management
    • Acute
    • Chronic

  • Distribution Channel Insights (Revenue, USD Mn, 2023 - 2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

  • Regional Insights (Revenue, USD Mn, 2023 - 2035)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa